AbbVie

Janssen/AbbVie drug approved in graft-versus-host disease

August 7, 2017

First use for Imbruvica outside blood cancer.

Janssen/AbbVie drug approved in graft-versus-host disease

https://pharmaphorum.com/news/imbruvica-drug-approved-graft-versus-host-disease/

FDA advisers reject J&J rheumatoid arthritis drug

August 3, 2017

Expert panel concerned about safety of sirukumab.

FDA advisers reject J&J rheumatoid arthritis drug

https://pharmaphorum.com/news/fda-advisers-reject-jj-arthritis/

Biogen MS drug hit by EU safety restriction

July 10, 2017

Regulators concerned over liver damage risk

Biogen MS drug hit by EU safety restriction

https://pharmaphorum.com/news/biogen-ms-drug-hit-eu-safety-restriction/

Regulators finally back Merck KGaA oral MS drug

June 26, 2017

A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green

Regulators finally back Merck KGaA oral MS drug

https://pharmaphorum.com/news/regulators-mavenclad/

AbbVie looks beyond Humira as RA pill meets phase 3 targets

June 8, 2017

Upadacitinib hopes drug will reduce reliance on Humira.

AbbVie looks beyond Humira as RA pill meets phase 3 targets

https://pharmaphorum.com/news/abbvie-looks-beyond-humira-ra-pill-meets-phase-3-targets/

Sanofi, Regeneron aim to undercut rivals with new RA drug

May 23, 2017

New drug will be sold at around 30% discount to rivals.

Sanofi, Regeneron aim to undercut rivals with new RA drug

https://pharmaphorum.com/news/sanofi-regeneron-new-ra-drug/

AbbVie’s 8-week hepatitis C drug granted early access in UK

May 11, 2017

AbbVie’s hepatitis C drug granted early access in UK

AbbVie’s 8-week hepatitis C drug granted early access in UK

https://pharmaphorum.com/news/abbvies-hepatitis-c-drug-granted-early-access-uk/

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

April 24, 2017

Trial backs patient-friendly regime in tough to treat strain.

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

https://pharmaphorum.com/news/abbvie-to-compete/

Doubts over AbbVie PARP inhibitor after double trial failure

April 20, 2017

Veliparib fails in two phase 3 trials.

Doubts over AbbVie PARP inhibitor after double trial failure

https://pharmaphorum.com/news/doubts-abbvie-parp-inhibitor-double-trial-failure/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com

Trending

AbbVie

Janssen/AbbVie drug approved in graft-versus-host disease

FDA advisers reject J&J rheumatoid arthritis drug

Biogen MS drug hit by EU safety restriction

Regulators finally back Merck KGaA oral MS drug

AbbVie looks beyond Humira as RA pill meets phase 3 targets

Sanofi, Regeneron aim to undercut rivals with new RA drug

AbbVie’s 8-week hepatitis C drug granted early access in UK

AbbVie takes aim at Gilead and BMS with 8-week hep C treatment

Doubts over AbbVie PARP inhibitor after double trial failure

7th Annual Partnership Opportunities in Drug Delivery (PODD)

2nd Annual RNA Therapeutics Summit

3rd Annual Pre-Filled Syringes Summit

Mylan finalises $465m deal with US government over EpiPen

FDA approves Pfizer’s Besponsa in aggressive blood cancer

AZ and Merck & Co ovarian cancer drug gets expanded US use

UCB recruits Belgian wearables firm for epilepsy study

Trump disbands business forums as CEOs quit

Digital health round-up: Apple vs Google

Spotlight on: The Future of Medical Affairs

AZ looks to pay-for-performance to bolster cardio-diabetes franchise

Medical Affairs – the heart of a data-driven, patient-centric pharma

Five questions: How are data and analytics transforming Medical Affairs?

Search

Advanced Search

Trending

AbbVie